Quick Takeaways
- ARMISTICE CAPITAL, LLC filed SCHEDULE 13G/A for TRAVERE THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (RMTI).
- Disclosed ownership: 10%.
- Date of event: 30 Jun 2025.
ARMISTICE CAPITAL, LLC - 30 Jun 2025 SCHEDULE 13G/A Report for TRAVERE THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (RMTI)
- Filing Manager
- ARMISTICE CAPITAL, LLC
- Reporting Manager
- Armistice Capital, LLC
- Symbol
- RMTI
- Shares outstanding
- 89,116,466 shares
- Disclosed Ownership
- 8,876,000 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 Aug 2025, 12:30:14 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ARMISTICE CAPITAL, LLC disclosed 10% ownership in TRAVERE THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (RMTI) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 Aug 2025, 12:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 10% | 8,876,000 | 0 | 8,876,000 | /s/ Steven Boyd | Steven Boyd - Managing Member | |
| Steven Boyd | 10% | 8,876,000 | 0 | 8,876,000 | /s/ Steven Boyd | Steven Boyd |